Corindus Announces Live Broadcast of Robotic-assisted PCI using CorPath® GRX to TCT Asia-Pacific Summit in South Korea
April 26 2017 - 6:45AM
Business Wire
Procedure transmitted live from Fu Wai Hospital
to over 4,000 attendees at 22nd annual TCT Asia-Pacific
Cardiovascular Summit
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading
developer of precision vascular robotics, announced today that Fu
Wai Hospital in China performed and broadcast live a PCI procedure
using the CorPath GRX System to more than 4,000 attendees at the
22nd annual TCT Asia-Pacific Cardiovascular Summit. The annual
conference, being held in Seoul, South Korea, attracts attendees
from 44 countries, with a majority of attendees from the
Asia-Pacific region.
The CorPath GRX System, temporarily placed at Fu Wai Hospital
for investigational use, is the first installation of the
next-generation CorPath System outside of the United States. Dr.
Kefei Dou, Deputy Director of Coronary Artery Disease for the
Department of Cardiology at Fu Wai Hospital, successfully performed
the first robotic-assisted PCI procedures in Asia in March, with
this case being the second one transmitted via live feed. Fu Wai
Hospital is the largest hospital in China and specializes in the
treatment, prevention and research of cardiovascular diseases and
hypertension and their related complications. According to
Millennium Research Group, China is the second largest PCI market
in the world.
"The Asia-Pacific region represents a variety of markets that
are strategically important as we continue to grow our business
internationally. We are encouraged by the positive feedback we have
received from physicians in response to both live cases regarding
the capability and potential for robotics in the region," said Tal
Wenderow, Corindus Co-Founder and Executive Vice President
International & Business Development.
"Having been involved in the first live case and on the panel
for the second, I am impressed with the speed with which Dr. Dou
and his team mastered the CorPath technology. The discussion around
the precision capabilities, applicability of robotics in complex
PCI, and the vision of where the technology can go has spurred
tremendous interest in the interventional community," said J. Aaron
Grantham, M.D., Corindus Chief Medical Officer.
CorPath GRX offers enhancements to the CorPath platform by
adding important key upgrades that increase precision, improve
workflow, and extend the capabilities and range of procedures that
can be performed robotically. Physicians now have independent and
simultaneous robotic control of guide catheters, guidewires, and
balloon/stent catheters, with one-millimeter advancement
capability, from the workstation console. This precise positioning
that allows physicians to adjust guide catheters during PCI
procedures may expand the use of the CorPath GRX System to more
complex cases.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to interventional procedures. During the procedure, the
interventional cardiologist sits at a radiation-shielded
workstation to advance guide catheters, stents, and guidewires with
millimeter-by-millimeter precision. The workstation allows the
physician greater control and the freedom from wearing heavy lead
protective equipment that causes musculoskeletal injuries. With the
CorPath System, Corindus Vascular Robotics brings robotic precision
to interventional procedures to help optimize clinical outcomes and
minimize the costs associated with complications of improper stent
placement during manual procedures. Corindus stands behind its
product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow
@CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements:
- that the Asia-Pacific region represents
a variety of markets that are strategically important as Corindus
continues to grow its business internationally,
- that discussion around the precision
capabilities, applicability of robotics in complex PCI, and the
vision of where the CorPath technology can go has spurred
tremendous interest in the interventional community, and
- that the precise positioning
enhancements to the CorPath platform that allows physicians to
adjust guide catheters during PCI procedures may expand the use of
the CorPath GRX System to more complex cases.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: the rate of adoption of our
CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170426005411/en/
Corindus Vascular Robotics, Inc.Media Contact:Kate
Stanton, 508-653-3335 ext.
200kate.stanton@corindus.comorInvestor Contact:Lynn Pieper
Lewis, 415-937-5402ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Apr 2023 to Apr 2024